| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥21.4B | - | - |
| Operating Income | ¥2.2B | - | - |
| Ordinary Income | ¥2.3B | - | - |
| Net Income | ¥1.4B | - | - |
| ROE | 4.7% | - | - |
FY2026 Q3 cumulative results show revenue of 21.4B yen, operating income of 2.2B yen (operating margin 10.2%), ordinary income of 2.3B yen, and net income of 1.4B yen. The company operates solely in the cell banking business segment. With gross profit margin at 61.7% and SG&A expenses at 11.0B yen (51.5% of revenue), profitability demonstrates high gross margin potential constrained by elevated operating expenses. Total assets stand at 80.3B yen with equity of 30.6B yen (equity ratio 38.1%), reflecting conservative capital structure. However, working capital management reveals significant concerns with extended receivables collection period. ROE of 4.7% remains subdued, primarily driven by low asset turnover of 0.267.
Revenue for the nine-month period reached 21.4B yen against full-year guidance of 30.0B yen, representing 71.5% progress rate. Cost of sales of 8.2B yen yielded gross profit of 13.2B yen with robust gross margin of 61.7%, indicating strong pricing power and service value proposition in the cell banking business. The high gross margin reflects the specialized nature of cell storage and related services requiring technical expertise and regulatory compliance.
Operating profit of 2.2B yen reflects SG&A expenses of 11.0B yen, which represent 51.5% of revenue and 83.3% of gross profit. The substantial SG&A burden relative to gross profit indicates ongoing investments in infrastructure, marketing, and operational support necessary for customer acquisition and service delivery in the specialized healthcare services sector. Operating margin of 10.2% demonstrates that while the business model generates strong gross margins, significant operating leverage improvement remains necessary to convert top-line growth into proportional profit expansion.
Ordinary income of 2.3B yen exceeded operating income by 0.1B yen, indicating modest positive contribution from non-operating items. Net income of 1.4B yen represents 59.6% of ordinary income, with the difference primarily attributable to income tax expense. The effective tax rate of approximately 36.9% is elevated relative to standard corporate tax rates, potentially reflecting limited tax optimization opportunities or non-deductible expenses.
The performance pattern represents revenue growth trajectory toward full-year targets with maintained profitability, though asset efficiency constraints and working capital management issues present significant operational improvement opportunities.
The company operates a single business segment in cell banking services, and segment reporting is omitted due to lack of materiality in segment breakdown. Cell banking represents the core and sole business, encompassing umbilical cord blood and tissue storage services. Revenue of 21.4B yen and operating income of 2.2B yen (margin 10.2%) reflect the consolidated performance of this single-segment business model.
[Profitability] ROE of 4.7% reflects subdued return on equity primarily driven by low asset turnover. Operating margin of 10.2% demonstrates positive operating leverage but remains constrained by SG&A expense burden at 51.5% of revenue. Net profit margin of 6.8% indicates profitability after tax burden of approximately 36.9% effective rate. Gross profit margin of 61.7% confirms strong underlying business economics with significant value creation at the service delivery level. [Cash Quality] Cash and deposits of 30.3B yen provide substantial liquidity coverage. Short-term debt coverage stands at 0.68x with minimal interest-bearing debt of 3.9B yen. However, receivables turnover reveals significant concern with DSO of approximately 390 days, indicating extended collection periods substantially exceeding industry norms and suggesting potential credit risk or contract structure issues. [Investment Efficiency] Asset turnover of 0.267 (revenue 21.4B yen divided by total assets 80.3B yen on annualized basis) reflects low capital efficiency, substantially below the IT and telecom industry median of 0.67. This indicates either asset-intensive business model requirements or suboptimal asset utilization. [Financial Health] Equity ratio of 38.1% provides moderate capital cushion. Current ratio of 122.2% (current assets 54.3B yen versus current liabilities 44.4B yen) indicates adequate short-term liquidity coverage. Debt-to-equity ratio of 0.13 reflects minimal leverage with interest-bearing debt of 3.9B yen against equity of 30.6B yen, indicating conservative financing policy.
Cash and deposits increased to 30.3B yen, representing 37.7% of total assets and providing substantial liquidity cushion. Net income of 1.4B yen contributed to earnings accumulation, though the translation to cash requires assessment of working capital movements. Current assets of 54.3B yen against current liabilities of 44.4B yen yield current ratio of 122.2%, confirming adequate coverage of short-term obligations. However, the extended receivables collection period of approximately 390 days indicates significant working capital tied up in outstanding customer balances, substantially constraining cash conversion efficiency. The minimal interest-bearing debt of 3.9B yen against total equity of 30.6B yen reflects low financial leverage, with debt coverage appearing manageable from the substantial cash position. The working capital structure reveals potential inefficiency with extended credit terms or collection challenges that may impact actual cash generation relative to reported earnings. Cash coverage of short-term liabilities stands at 0.68x, suggesting reliance on operating cash generation and current asset liquidation for near-term obligations.
Ordinary income of 2.3B yen versus operating income of 2.2B yen shows non-operating net contribution of approximately 0.1B yen, representing minimal impact at 0.5% of revenue. The small positive spread indicates limited reliance on non-operating gains to support headline profitability. Non-operating income comprises primarily financial income and miscellaneous items that do not materially distort core business performance assessment. The alignment between operating and ordinary income levels confirms earnings quality derives predominantly from core cell banking operations rather than one-time gains or financial engineering. The gap between ordinary income of 2.3B yen and net income of 1.4B yen reflects tax burden, with effective tax rate of 36.9% reducing post-tax profitability. While operating cash flow data is unavailable for quarterly reporting, the substantial cash position of 30.3B yen relative to net income suggests historical cash generation capability. However, the extended receivables collection period of 390 days raises concerns about earnings quality from a cash conversion perspective, indicating potential timing differences between revenue recognition and actual cash receipt that warrant monitoring for sustainable earnings assessment.
Full-year guidance targets revenue of 30.0B yen, operating income of 4.5B yen (margin 15.0%), and ordinary income of 4.5B yen. Q3 cumulative progress shows revenue at 21.4B yen (71.5% of guidance), operating income at 2.2B yen (48.9% of guidance), and ordinary income at 2.3B yen (51.1% of guidance). Revenue progress of 71.5% exceeds the standard Q3 benchmark of 75% by only -3.5 percentage points, indicating generally on-track top-line trajectory. However, operating income progress of 48.9% lags the 75% benchmark by -26.1 percentage points, signaling significant Q4 profit acceleration required to meet full-year targets. The operating margin gap between Q3 actual of 10.2% and full-year guidance of 15.0% suggests expectation of improved operating leverage in Q4, potentially through seasonal revenue concentration, SG&A expense timing, or one-time items. Achieving the remaining 8.6B yen revenue (40.2% of full-year target) and 2.3B yen operating income (51.1% of full-year target) in Q4 alone would require substantial quarterly performance exceeding historical run rates. The forecast EPS of 31.46 yen against Q3 actual EPS of 14.50 yen implies expected Q4 EPS of approximately 16.96 yen. No specific forecast assumptions or revisions are disclosed in the available data. The achievement probability depends on Q4 revenue acceleration, SG&A cost control, and collection of outstanding receivables to support cash-based performance.
Extended receivables collection period of 390 days represents the most critical operational risk, indicating either extended credit terms inherent in customer contracts or collection difficulties. This substantially exceeds the IT and telecom industry median receivables turnover of 61 days by more than six times, tying up significant working capital and creating potential credit loss exposure. The concentration should be monitored for aging analysis, customer creditworthiness, and contract terms that may necessitate reserves or collection acceleration efforts.
Single business segment concentration in cell banking services creates revenue dependency on a specialized healthcare niche subject to regulatory changes, medical practice trends, and competitive dynamics. Any adverse developments in reimbursement policies, clinical evidence supporting cell banking efficacy, or competitive service offerings could materially impact the entire revenue base without diversification buffers.
Q4 profit acceleration requirement to achieve full-year guidance represents execution risk, with operating income needing to reach approximately 2.3B yen in Q4 alone compared to 2.2B yen achieved across the first nine months. This implies Q4 operating margin substantially exceeding year-to-date levels, dependent on revenue seasonality, cost control, or non-recurring items that may not materialize as planned.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE of 4.7% substantially underperforms the IT and telecom industry median of 8.3% (2025-Q3, n=104), placing the company in the lower performance quartile. Operating margin of 10.2% exceeds the industry median of 8.2% (IQR: 3.6%-18.0%), indicating above-median operational profitability despite low return on equity. Net profit margin of 6.8% aligns closely with the industry median of 6.0% (IQR: 2.2%-12.7%).
Financial Health: Equity ratio of 38.1% falls below the industry median of 59.2% (IQR: 42.5%-72.7%), indicating higher leverage utilization relative to peers. Current ratio of 1.22x significantly underperforms the industry median of 2.15x (IQR: 1.57x-3.62x), suggesting tighter short-term liquidity positioning.
Efficiency: Asset turnover of 0.267 substantially lags the industry median of 0.67 (IQR: 0.49-0.93), representing the primary driver of underperforming ROE. This places the company below the 25th percentile for capital efficiency. Receivables turnover of approximately 390 days dramatically exceeds the industry median of 61 days (IQR: 46-83 days), indicating severe working capital inefficiency relative to sector norms.
The company demonstrates sector-competitive operating margins but faces significant challenges in asset efficiency and working capital management that constrain overall returns. The extended receivables collection substantially differentiates the company's cash conversion profile from industry peers.
(Industry: IT and Telecom, Comparison: FY2025-Q3 benchmark period, Source: Proprietary analysis)
The company's financial profile reveals a specialized healthcare services business model with strong gross margins of 61.7% reflecting valuable service positioning in cell banking, but facing significant operational efficiency constraints. Operating margin of 10.2% demonstrates positive but limited operating leverage given the substantial SG&A burden at 51.5% of revenue, indicating opportunity for profit margin expansion through either revenue scale or cost structure optimization.
The most distinctive characteristic is the extended receivables collection period of 390 days, dramatically exceeding industry norms and tying up substantial working capital. This represents either industry-specific contract structures requiring extended billing cycles or execution challenges in collections management. Resolution of this working capital inefficiency would materially improve cash conversion, reduce financing needs, and potentially support higher shareholder returns. The current asset efficiency ratio of 0.267 substantially below industry median of 0.67 directly contributes to subdued ROE of 4.7% despite acceptable profit margins.
Financial positioning remains conservative with minimal debt leverage (debt-to-equity 0.13) and substantial cash holdings of 30.3B yen, providing flexibility for growth investments or enhanced shareholder returns. However, achieving full-year profit guidance requires significant Q4 acceleration with operating income needing to approximately double Q1-Q3 run rates, presenting execution risk. The specialized single-segment business model creates both opportunity for category leadership and concentration risk requiring sustained competitive positioning in the cell banking services market.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.